Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.

Cancer cell - 19 Jan 2010

Turke Alexa B, Zejnullahu Kreshnik, Wu Yi-Long, Song Youngchul, Dias-Santagata Dora, Lifshits Eugene, Toschi Luca, Rogers Andrew, Mok Tony, Sequist Lecia, Lindeman Neal I, Murphy Carly, Akhavanfard Sara, Yeap Beow Y, Xiao Yun, Capelletti Marzia, Iafrate A John, Lee Charles, Christensen James G, Engelman Jeffrey A, Jänne Pasi A

Abstract excerpt

MET amplification activates ERBB3/PI3K/AKT signaling in EGFR mutant lung cancers and causes resistance to EGFR kinase inhibitors. We demonstrate that MET activation by its ligand, HGF, also induces drug resistance, but through GAB1 signaling. Using high-throughput FISH analyses in both cell lines...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Neoplasm
Share to Gene Amplification

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatocyte Growth Factor

Share to In Situ Hybridization, Fluorescence

Share to Proto-Oncogene Proteins c-met

Share to Quinazolinones

Share to Receptors, Growth Factor

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 20129249
DOI: 10.1016/j.ccr.2009.11.022
PMCID: PMC2980857

Genes

MET
EGFR
HGF
ERBB3
GAB1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20129249-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.PMID 20129249Read ↗

Met inhibitors in the treatment of lung cancer: the evidence to date.Semantic proximity Read ↗

Clinical Implications of <i>MET</i> Gene Copy Number in Lung CancerSemantic proximity Read ↗

Targeting MET in EGFR-Mutated NSCLC.Semantic proximity Read ↗

MET amplification identified by next-generation sequencing and its clinical relevance for MET inhibitorsSemantic proximity Read ↗

Unraveling the Significance of MET Focal Amplification in Lung Cancer: Integrative NGS, FISH, and IHC Investigation.Semantic proximity Read ↗

Molecular heterogeneity and co-altered genes in MET-amplified ALK-positive lung cancer: Implications for MET targeted therapy.Semantic proximity Read ↗

Targeting MET Dysregulation in CancerSemantic proximity Read ↗

Lung Cancer Cell Lines Harboring <i>MET</i> Gene Amplification Are Dependent on Met for Growth and SurvivalSemantic proximity Read ↗

Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of EGFR-mutant lung cancer.Semantic proximity Read ↗

The Met receptor tyrosine kinase: a key player in oncogenesis and drug resistance.Semantic proximity Read ↗

Acquired MET Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Clonal MET Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.